Literature DB >> 12502877

Baseline susceptibility of primary human immunodeficiency virus type 1 to entry inhibitors.

Béatrice Labrosse1, Jean-Louis Labernardière, Elisabeth Dam, Virginie Trouplin, Katharina Skrabal, François Clavel, Fabrizio Mammano.   

Abstract

Human immunodeficiency virus type 1 plasma viruses from 29 entry inhibitor-naive patients were characterized for their susceptibilities to T-20, AMD3100, and RANTES. A strikingly wide range of susceptibilities to T-20 was observed that was influenced by coreceptor usage but not by the susceptibilities of the viruses to inhibitors that target the chemokine receptors or by polymorphisms in the gp41 N helix.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12502877      PMCID： PMC140831          DOI： 10.1128/jvi.77.2.1610-1613.2003

Source DB:  PubMed          Journal:  J Virol        ISSN： 0022-538X            Impact factor:   5.103


  26 in total

1.  Inhibition of HIV-1 entry before gp41 folds into its fusion-active conformation.

Authors:  Y Kliger; Y Shai
Journal:  J Mol Biol       Date:  2000-01-14       Impact factor: 5.469

2.  gp120: Biologic aspects of structural features.

Authors:  P Poignard; E O Saphire; P W Parren; D R Burton
Journal:  Annu Rev Immunol       Date:  2001       Impact factor: 28.527

Review 3.  Chemokine receptors as anti-retroviral targets.

Authors:  N Heveker
Journal:  Curr Drug Targets       Date:  2001-03       Impact factor: 3.465

4.  Primary genotypic resistance of HIV-1 to the fusion inhibitor T-20 in long-term infected patients.

Authors:  B Zöllner; H H Feucht; M Schröter; P Schäfer; A Plettenberg; A Stoehr; R Laufs
Journal:  AIDS       Date:  2001-05-04       Impact factor: 4.177

5.  Sensitivity of human immunodeficiency virus type 1 to the fusion inhibitor T-20 is modulated by coreceptor specificity defined by the V3 loop of gp120.

Authors:  C A Derdeyn; J M Decker; J N Sfakianos; X Wu; W A O'Brien; L Ratner; J C Kappes; G M Shaw; E Hunter
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

Review 6.  HIV-1 entry inhibitors in the side pocket.

Authors:  J G Sodroski
Journal:  Cell       Date:  1999-10-29       Impact factor: 41.582

Review 7.  Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease.

Authors:  E A Berger; P M Murphy; J M Farber
Journal:  Annu Rev Immunol       Date:  1999       Impact factor: 28.527

8.  Sensitivity of human immunodeficiency virus type 1 to fusion inhibitors targeted to the gp41 first heptad repeat involves distinct regions of gp41 and is consistently modulated by gp120 interactions with the coreceptor.

Authors:  C A Derdeyn; J M Decker; J N Sfakianos; Z Zhang; W A O'Brien; L Ratner; G M Shaw; E Hunter
Journal:  J Virol       Date:  2001-09       Impact factor: 5.103

9.  Determination of coreceptor usage of human immunodeficiency virus type 1 from patient plasma samples by using a recombinant phenotypic assay.

Authors:  V Trouplin; F Salvatori; F Cappello; V Obry; A Brelot; N Heveker; M Alizon; G Scarlatti; F Clavel; F Mammano
Journal:  J Virol       Date:  2001-01       Impact factor: 5.103

Review 10.  The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens.

Authors:  R Wyatt; J Sodroski
Journal:  Science       Date:  1998-06-19       Impact factor: 47.728
View more
  36 in total

1.  A small molecule HIV-1 inhibitor that targets the HIV-1 envelope and inhibits CD4 receptor binding.

Authors:  Pin-Fang Lin; Wade Blair; Tao Wang; Timothy Spicer; Qi Guo; Nannan Zhou; Yi-Fei Gong; H-G Heidi Wang; Ronald Rose; Gregory Yamanaka; Brett Robinson; Chang-Ben Li; Robert Fridell; Carol Deminie; Gwendeline Demers; Zheng Yang; Lisa Zadjura; Nicholas Meanwell; Richard Colonno
Journal:  Proc Natl Acad Sci U S A       Date:  2003-08-20       Impact factor: 11.205

2.  Intrinsic obstacles to human immunodeficiency virus type 1 coreceptor switching.

Authors:  Cristina Pastore; Alejandra Ramos; Donald E Mosier
Journal:  J Virol       Date:  2004-07       Impact factor: 5.103

3.  Baseline genotypic and phenotypic susceptibilities of HIV-1 group O to enfuvirtide.

Authors:  Agnès Depatureaux; Charlotte Charpentier; Gilles Collin; Marie Leoz; Diane Descamps; Aurélia Vessière; Florence Damond; Dominique Rousset; Françoise Brun-Vézinet; Jean-Christophe Plantier
Journal:  Antimicrob Agents Chemother       Date:  2010-06-14       Impact factor: 5.191

Review 4.  Emerging drug targets for antiretroviral therapy.

Authors:  Jacqueline D Reeves; Andrew J Piefer
Journal:  Drugs       Date:  2005       Impact factor: 9.546

5.  The cytoplasmic tail slows the folding of human immunodeficiency virus type 1 Env from a late prebundle configuration into the six-helix bundle.

Authors:  Levon G Abrahamyan; Samvel R Mkrtchyan; James Binley; Min Lu; Grigory B Melikyan; Fredric S Cohen
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

6.  Clinical resistance to enfuvirtide does not affect susceptibility of human immunodeficiency virus type 1 to other classes of entry inhibitors.

Authors:  Neelanjana Ray; Jessamina E Harrison; Leslie A Blackburn; Jeffrey N Martin; Steven G Deeks; Robert W Doms
Journal:  J Virol       Date:  2007-01-24       Impact factor: 5.103

Review 7.  HIV-1 drug resistance mutations: an updated framework for the second decade of HAART.

Authors:  Robert W Shafer; Jonathan M Schapiro
Journal:  AIDS Rev       Date:  2008 Apr-Jun       Impact factor: 2.500

8.  HIV-1 Transmission, Replication Fitness and Disease Progression.

Authors:  Tasha Biesinger; Jason T Kimata
Journal:  Virology (Auckl)       Date:  2008-07-14

9.  Genotype and phenotype patterns of human immunodeficiency virus type 1 resistance to enfuvirtide during long-term treatment.

Authors:  Stefano Menzo; Antonella Castagna; Alessia Monachetti; Hamid Hasson; Anna Danise; Elisabetta Carini; Patrizia Bagnarelli; Adriano Lazzarin; Massimo Clementi
Journal:  Antimicrob Agents Chemother       Date:  2004-09       Impact factor: 5.191

10.  Elite suppressor-derived HIV-1 envelope glycoproteins exhibit reduced entry efficiency and kinetics.

Authors:  Kara G Lassen; Michael A Lobritz; Justin R Bailey; Samantha Johnston; Sandra Nguyen; Benhur Lee; Tom Chou; Robert F Siliciano; Martin Markowitz; Eric J Arts
Journal:  PLoS Pathog       Date:  2009-04-10       Impact factor: 6.823
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.